The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
@PJT12 - There are so many variables from my point of view, Bent is one word, manipulated is another word the list can go on, we can only sit on the side-lines and make any informed decisions based on our own gut instincts, personally, as a LTH my hands are well away from the sell button.
https://twitter.com/angusenergyplc/status/1595061027296915458?s=20&t=CfKsT_j4nnk76aezvTyi6w
@Windows345 - Thank you!
Hi - Can anyone share L2 data please, I'm keen to see what the MM's are holding and at what price.
Thanks in advance.
@AM01 - I cant see where this relates to CBX?
Apoligses if you have already had sight of this.
The LD acquisition (60 employees) provides #AVCT’s diagnostics division with scale & critical mass at an attractive entry price (equivalent to a 1.35x EV/sales). Adding an est £17.9m of turnover (£14.2m IVD tests + £3.7m Covid) at 44%-50% gross margins. On top of EU-wide distribution across the UK, France & Benelux, where its supplies a range of 4,012 products to >500 customers. Typically these contracts are with the NHS, hospitals, clinical trial / cancer centres and commercial laboratories - last between 3 to 5 years and generate 95% repeat revenues.
The strategy ultimately being to create a major European diagnostics business - selling both 3rd party & in-house products, covering respiratory infections, cardiovascular disease, cancer and general health & well-being.
Next, attracting such an accomplished, technology investor like Heights Capital – who has probably also performed substantial amounts of due diligence – provides enormous confidence in Avacta’s prospects. Not only in the efficacy of its Affimer platform, but also the ground breaking pre|CISION technology, which is scheduled to release key Phase 1a clinical trial data shortly wrt its flagship cancer busting AVA6000 Pro-doxorubicin drug.
Lastly, the fund raise will provide a much longer cash runway for the group. In fact at the end of June, #AVCT reported net cash of £17m. Meaning that I estimate there will still be circa £40m+ in the bank at Dec’22 - providing ample fire-power to execute on its extensive R&D efforts, 3rd party licensing deals and commercialisation plans.
CEO Alastair Smith commenting: "This financing allows us to progress our M&A-led growth strategy for Avacta's diagnostics division and a pipeline of potential acquisitions in the European diagnostics sector to build a fully integrated and differentiated diagnostics business with global reach. Alongside the continued funding of Avacta's Therapeutics division to progress AVA6000 through the clinic and further develop the broader oncology pipeline."
@Fruitsnveg - What we see/gets published is one thing but the reality as you spotted can be something else, the only word I can think off and have seen many times in manipulation by the MM's, I have no hard evidence of this but have seen situations over the years that clearly don't make any sense, or, what I/we all see... GLA.